JointHealth™ express   June 15, 2017

Reminder: Let BC PharmaCare hear "Your Voice" on biosimilar etanercept

BC PharmaCare is looking for your input on biosimilar etanercept (Erelzi) for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis and rheumatoid arthritis

Biosimilar etanercept (Erelzi) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. You can give input if you are a B.C. resident and have AS, JIA or RA, a caregiver to someone with AS, JIA or RA, or if your group represents people who live with AS, JIA or RA.

If you would like our help in providing your input, you can email us your input at or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Monday, June 19 so that we may submit the questionnaire in time for the deadline.

The submission deadline is 11:59pm on June 21, 2017. Patients and caregivers may give their input directly through the links below:
  • To view the information sheet for biosimilar etanerept (Erelzi) for ankylosing spondylitis, juvenile arthritis and rheumatoid arthritis: click here
  • For the Patient Questionnaire: click here
  • For the Caregiver Questionnaire: click here
  • For the Patient Group Questionnaire: click here
  • (Patient groups are required to register their name with the Ministry of Health before making their submission.)